miR-552: an important post-transcriptional regulator that affects human cancer

Zou, Yuhao; Zhao, Xin; Li, Yin; Duan, Shiwei

doi:10.7150/jca.46613

Cited by 18 publications

(16 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This miRNA has been shown to be a circulating biomarker of distant metastasis into the lung and the liver (76, 77), it also regulates adenomas via signaling pathways such as MAPK, PTEN/AKT, and STAT (78, 79). In cluster C, we also found a significant targeting role for miR-552-3p, which has been associated with liver cancer and regulates various hallmarks of cancer (80). Supplementary material provides an examination of the relationship between PanomiR miRNAs with DE miRNAs in TP vs NT.…”

Section: Resultsmentioning

confidence: 73%

PanomiR: A systems biology framework for analysis of multi-pathway targeting by miRNAs

Yeganeh

Teo

Karagkouni

et al. 2022

Preprint

View full text Add to dashboard Cite

Charting miRNA regulation across multiple pathways is central to characterizing their role in disease. Yet, current methods expose only isolated miRNA-pathway interactions. We have developed a systems biology approach, Pathway networks of miRNA Regulation (PanomiR) that identifies miRNAs that coordinately target groups of pathways. PanomiR captures activity dynamics of pathways, detects dysregulated pathways, groups pathways by their co-expression, and detects miRNAs that specifically target these coordinated groups of dysregulated pathways. We have used PanomiR to explore disease-associated miRNAs and pathways in liver cancer. We show that it recapitulates known and novel liver cancer pathways, determines their up or down regulation, and sensitively captures biologically meaningful signals independent of detectable differential gene expression. PanomiR organizes liver cancer pathways into three broad groups that reflect pathogenic mechanisms of cancer: activation of transcription, cell cycle and proliferation, and dysregulated signalling. Using either experimentally-supported or predicted miRNA-mRNA interactions, PanomiR robustly detects and identifies miRNAs central to liver cancer, unbiased by the number of their gene targets-making it possible to place these cancer miRNAs using PanomiR into the context of co-activated pathways that they regulate. PanomiR is a sensitive, unbiased framework for detection of disease-specific multi-pathway programs under miRNA regulation. PanomiR is accessible as an open-source R/Bioconductor package: <https://bioconductor.org/packages/PanomiR>.

show abstract

Section: Resultsmentioning

confidence: 73%

PanomiR: A systems biology framework for analysis of multi-pathway targeting by miRNAs

Yeganeh

Teo

Karagkouni

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…The miR-552 is located on chromosome 1p34.3 and encodes a small non-coding RNA involved in post-transcriptional regulation. The two main members of this family are hsa-miR-552-5p and hsa-miR-552-3p, which are highly conserved [11]. miR-552 is significantly overexpressed in several tumor types, where it drives cell proliferation, invasion, migration, and drug resistance, thereby accelerating tumorigenesis [12][13][14].…”

Section: Ivyspringmentioning

confidence: 99%

Exosomal miR-552-5p promotes tumorigenesis and disease progression via the PTEN/TOB1 axis in gastric cancer

Zhu¹,

Zhang²,

Chen³

et al. 2022

J. Cancer

View full text Add to dashboard Cite

Purpose Gastric cancer (GC) is associated with rapid disease progression and poor patient prognosis, highlighting the pressing need for new biomarkers to facilitate disease management. Exosomes are released by all cells and are ubiquitous in body fluids, thus giving them great potential as diagnostic biomarkers and therapeutic targets. MicroRNAs (miRNAs) can be transported by exosomes, and are a common target for regulation in cancer. Methods Our screen of miRNAs in the Gene Expression Omnibus and The Cancer Genome Atlas databases identified miR-552-5p as the most overexpressed miRNA in GC, and we investigated its function and mechanism of action. ResultsWe detected high expression of miR-552-5p in GC tissues, plasma samples and cell lines. We found that miR-552-5p binds directly to the 3′-untranslated region of PTEN, and the resulting downregulation of PTEN in turn downregulates the tumor suppressor TOB1. Furthermore, experiments in cell culture and mice showed that miR-552-5p in exosomes is internalized by recipient cells, where it enhances proliferation, migration and the epithelial-mesenchymal transition, while suppressing the caspase-3 apoptotic pathway. These effects were reversed by inhibiting miR-552-5p. Conclusion GC-derived exosomal miR-552-5p facilitates tumorigenesis by interfering with the PTEN/TOB1 axis, providing new potential therapeutic targets.

show abstract

“…A research-based on RT-PCR, Western blot, and bioinformatics analysis detected for the first time a significant upregulation of miRNA-552 in ovarian malignant tumors [ 113 ]. Their findings suggested that miRNA-552 associated with the PTEN gene (Phosphatase and tensin homolog) can be used for anticipation of the patient prognosis and tumor recurrence [ 113 , 117 ].…”

Section: Biomarkers In the Management And Prognosis Of Ovarian Cancermentioning

confidence: 99%

Ovarian Cancer: Biomarkers and Targeted Therapy

et al. 2021

View full text Add to dashboard Cite

Ovarian cancer is one of the most common causes of death in women as survival is highly dependent on the stage of the disease. Ovarian cancer is typically diagnosed in the late stage due to the fact that in the early phases is mostly asymptomatic. Genomic instability is one of the hallmarks of ovarian cancer. While ovarian cancer is stratified into different clinical subtypes, there still exists extensive genetic and progressive diversity within each subtype. Early detection of the disorder is one of the most important steps that facilitate a favorable prognosis and a good response to medical therapy for the patients. In targeted therapies, individual patients are treated by agents targeting the changes in tumor cells that help them grow, divide and spread. Currently, in gynecological malignancies, potential therapeutic targets include tumor-intrinsic signaling pathways, angiogenesis, homologous-recombination deficiency, hormone receptors, and immunologic factors. Ovarian cancer is usually diagnosed in the final stages, partially due to the absence of an effective screening strategy, although, over the times, numerous biomarkers have been studied and used to assess the status, progression, and efficacy of the drug therapy in this type of disorder.

show abstract

miR-552: an important post-transcriptional regulator that affects human cancer

Cited by 18 publications

References 77 publications

PanomiR: A systems biology framework for analysis of multi-pathway targeting by miRNAs

PanomiR: A systems biology framework for analysis of multi-pathway targeting by miRNAs

Exosomal miR-552-5p promotes tumorigenesis and disease progression via the PTEN/TOB1 axis in gastric cancer

Ovarian Cancer: Biomarkers and Targeted Therapy

Contact Info

Product

Resources

About